Metyrapone
Metopirone (metyrapone) is a small molecule pharmaceutical. Metyrapone was first approved as Metopirone on 1982-01-01. The pharmaceutical is active against cytochrome P450 11B1, mitochondrial. In addition, it is known to target cytochrome P450 11B2, mitochondrial.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Metopirone
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metyrapone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| METOPIRONE | HRA Pharma | N-012911 RX | 1996-08-09 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| metopirone | New Drug Application | 2023-11-13 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 1 | 1 | 1 | — | 4 |
| Depression | D003863 | — | F33.9 | — | 1 | 1 | 1 | — | 3 |
| Syndrome | D013577 | — | — | — | — | 1 | 1 | 1 | 3 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | — | — | 1 | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | — | F17 | 2 | 2 | 1 | — | — | 3 |
| Cushing syndrome | D003480 | EFO_0003099 | E24 | — | — | 1 | — | 1 | 2 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | 1 | — | — | 1 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 4 | 1 | — | — | 1 | 6 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Adrenocortical carcinoma | D018268 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | — | — | — | — | 1 |
| Intravenous infusions | D007262 | — | — | 1 | — | — | — | — | 1 |
| Starvation | D013217 | — | T73.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adrenal insufficiency | D000309 | — | — | — | — | — | — | 1 | 1 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | — | — | — | — | 1 | 1 |
| Craniocerebral trauma | D006259 | — | S00 | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | — | — | — | 1 | 1 |
| Adrenocortical hyperfunction | D000308 | EFO_1000797 | — | — | — | — | — | 1 | 1 |
| Hyperphagia | D006963 | — | R63.2 | — | — | — | — | 1 | 1 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Metyrapone |
| INN | metyrapone |
| Description | Metyrapone is an aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency. It has a role as a diagnostic agent, an antimetabolite and an EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C(=O)c1cccnc1)c1cccnc1 |
Identifiers
| PDB | — |
| CAS-ID | 54-36-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL934 |
| ChEBI ID | 44241 |
| PubChem CID | 4174 |
| DrugBank | DB01011 |
| UNII ID | ZS9KD92H6V (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,456 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
603 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use